Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Operating Expenses (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Operating Expenses for 5 consecutive years, with $15.2 million as the latest value for Q4 2025.

  • For Q4 2025, Operating Expenses fell 29.68% year-over-year to $15.2 million; the TTM value through Dec 2025 reached $59.1 million, down 34.76%, while the annual FY2025 figure was $59.1 million, 34.76% down from the prior year.
  • Operating Expenses hit $15.2 million in Q4 2025 for Kezar Life Sciences, up from $11.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $34.6 million in Q4 2023 and bottomed at $11.7 million in Q3 2025.
  • Average Operating Expenses over 5 years is $19.7 million, with a median of $18.3 million recorded in 2022.
  • Year-over-year, Operating Expenses skyrocketed 72.65% in 2023 and then crashed 46.62% in 2025.
  • Kezar Life Sciences' Operating Expenses stood at $14.1 million in 2021, then soared by 42.05% to $20.0 million in 2022, then surged by 72.65% to $34.6 million in 2023, then tumbled by 37.66% to $21.6 million in 2024, then decreased by 29.68% to $15.2 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $15.2 million, $11.7 million, and $14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.